Robert B M Landewe
Overview
Explore the profile of Robert B M Landewe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
4644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frazzei G, Landewe R, Wagenaar C, van de Stadt L, van Schaardenburg D, Tas S, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39956700
Objectives: The aim of this study was to predict rheumatoid arthritis (RA) development in a cohort of at-risk individuals with arthralgia positive for anti-citrullinated protein antibodies (ACPA) and/or rheumatoid factor...
2.
Deodhar A, Akar S, Curtis J, El-Zorkany B, Magrey M, Wang C, et al.
Adv Rheumatol
. 2024 Dec;
64(1):87.
PMID: 39695887
Objectives: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020)...
3.
Frazzei G, Cramer S, Landewe R, Maijer K, Gerlag D, Tak P, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39424405
Objectives: Early treatment of individuals at risk of developing rheumatoid arthritis (RA-risk) in the preclinical phase has the potential to positively impact both patients and society by preventing disease onset...
4.
Maldonado-Ficco H, Lopez-Medina C, Perez-Alamino R, Waimann C, Maldonado-Cocco J, Molto A, et al.
Rheumatology (Oxford)
. 2024 Oct;
PMID: 39361425
Objectives: Uveitis is a common extra-musculoskeletal manifestation in Spondyloarthritis (SpA). The aim of this study was to analyze the prevalence of uveitis in SpA patients, its association with geographical areas...
5.
Mease P, Merola J, Tanaka Y, Gossec L, McInnes I, Ritchlin C, et al.
Rheumatol Ther
. 2024 Aug;
11(5):1363-1382.
PMID: 39215949
Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and...
6.
7.
Drouet J, Lopez-Medina C, Granger B, Fautrel B, Landewe R, Molto A, et al.
Rheumatol Int
. 2024 Apr;
44(8):1455-1468.
PMID: 38597981
Global health (GH) and health-related quality of life are patient priorities in axial spondyloarthritis (axSpA). Our objective was to assess the relative importance of disease-related factors including disease activity, and...
8.
Landewe R
Lancet Rheumatol
. 2024 Jan;
3(4):e306-e312.
PMID: 38279413
The high prices of biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) put pressure on the health-care budgets for patients with rheumatic musculoskeletal diseases. High prices appear to reflect added...
9.
Landewe R, Sepriano A, Bergstra S
Semin Arthritis Rheum
. 2024 Jan;
64S:152316.
PMID: 38218699
Biological- or targeted-synthetic DMARD-responses reported in randomized clinical trials, placebo-controlled or head-to-head, in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis are unbelievably similar, when looking across trials performed in...
10.